{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:35:37Z","timestamp":1788910537398,"version":"build-2803163510"},"reference-count":275,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>In recent years, there have been a growing number of small and large molecules that could be used to treat diseases of the central nervous system (CNS). Nose-to-brain delivery can be a potential option for the direct transport of molecules from the nasal cavity to different brain areas. This review aims to provide a compilation of current approaches regarding drug delivery to the CNS via the nose, with a focus on biologics. The review also includes a discussion on the key benefits of nasal delivery as a promising alternative route for drug administration and the involved pathways or mechanisms. This article reviews how the application of various auxiliary agents, such as permeation enhancers, mucolytics, in situ gelling\/mucoadhesive agents, enzyme inhibitors, and polymeric and lipid-based systems, can promote the delivery of large molecules in the CNS. The article also includes a discussion on the current state of intranasal formulation development and summarizes the biologics currently in clinical trials. It was noted that significant progress has been made in this field, and these are currently being applied to successfully transport large molecules to the CNS via the nose. However, a deep mechanistic understanding of this route, along with the intimate knowledge of various excipients and their interactions with the drug and nasal physiology, is still necessary to bring us one step closer to developing effective formulations for nasal\u2013brain drug delivery.<\/jats:p>","DOI":"10.3390\/pharmaceutics16010066","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T10:01:06Z","timestamp":1704016866000},"page":"66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders"],"prefix":"10.3390","volume":"16","author":[{"given":"Elizabeth J.","family":"Patharapankal","sequence":"first","affiliation":[{"name":"Medway School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime, Canterbury ME4 4TB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adejumoke Lara","family":"Ajiboye","sequence":"additional","affiliation":[{"name":"Medway School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime, Canterbury ME4 4TB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mattern","sequence":"additional","affiliation":[{"name":"MetP Pharma AG, Schynweg 7, 6376 Emmetten, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-9214","authenticated-orcid":false,"given":"Vivek","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Medway School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime, Canterbury ME4 4TB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/03639040802020536","article-title":"CNS disorders\u2014Current treatment options and the prospects for Advanced Therapies","volume":"34","author":"Williams","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for Central Nervous System Disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2015.12.041","article-title":"Concepts, technologies, and practices for drug delivery past the blood\u2013brain barrier to the Central Nervous System","volume":"240","author":"Crawford","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1359-6446(01)02082-7","article-title":"Why is the global CNS pharmaceutical market so under-penetrated?","volume":"7","author":"Pardridge","year":"2002","journal-title":"Drug Discov. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejpb.2013.09.014","article-title":"One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats","volume":"85","author":"Khafagy","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.peptides.2010.04.011","article-title":"Nap (davunetide) enhances cognitive behavior in the stop heterozygous mouse\u2014A microtubule-deficient model of schizophrenia","volume":"31","author":"Pikman","year":"2010","journal-title":"Peptides"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(03)00039-5","article-title":"Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats","volume":"255","author":"Dufes","year":"2003","journal-title":"Int. J. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pneurobio.2007.10.008","article-title":"Urocortin and the brain","volume":"84","author":"Pan","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/jps.2600821124","article-title":"Transmucosal delivery of leucine enkephalin: Stabilization in rabbit enzyme extracts and enhancement of permeation through mucosae","volume":"82","author":"Sayani","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101530","DOI":"10.1016\/j.mcp.2020.101530","article-title":"A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis","volume":"51","author":"Acharya","year":"2020","journal-title":"Mol. Cell. Probes"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Niikura, T., Sidahmed, E., Hirata-Fukae, C., Aisen, P.S., and Matsuoka, Y. (2011). A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016259"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yfrne.2009.05.005","article-title":"Oxytocin, vasopressin, and human social behaviour","volume":"30","author":"Heinrichs","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"ref_15","first-page":"179","article-title":"Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS","volume":"18","author":"Lee","year":"2009","journal-title":"J. Drug Target."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/17425247.2011.588204","article-title":"Intranasal delivery of therapeutic proteins for neurological diseases","volume":"8","author":"Malerba","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.114.216705","article-title":"Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin","volume":"351","author":"Falcone","year":"2014","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuropharm.2018.05.002","article-title":"Intranasally delivered small interfering RNA-mediated suppression of scavenger receptor mac-1 attenuates microglial phenotype switching and working memory impairment following hypoxia","volume":"137","author":"Das","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","article-title":"Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes","volume":"17","author":"Dhaliwal","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gt.2014.28","article-title":"Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain","volume":"21","author":"Harmon","year":"2014","journal-title":"Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: Potential therapy for parkinson\u2019s disease","volume":"26","author":"Recasens","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jddst.2017.11.013","article-title":"Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain","volume":"43","author":"Song","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2017.04.059","article-title":"Limiting the level of tertiary amines on polyamines leads to biocompatible nucleic acid vectors","volume":"526","author":"Zheng","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00109-006-0114-9","article-title":"Enhanced brain targeting efficiency of intranasally administered plasmid DNA: An alternative route for brain gene therapy","volume":"85","author":"Han","year":"2007","journal-title":"J. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pneurobio.2009.07.001","article-title":"Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance","volume":"89","author":"Zheng","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1016\/j.bmc.2015.07.022","article-title":"Synthesis of CNS active thyrotropin-releasing hormone (TRH)-like peptides: Biological evaluation and effect on cognitive impairment induced by cerebral ischemia in mice","volume":"23","author":"Meena","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"137054","DOI":"10.1016\/j.neulet.2023.137054","article-title":"Effects of intra-nasal melanocortin-4 receptor antagonist on trigeminal neuropathic pain in male and female rats","volume":"796","author":"Korczeniewska","year":"2023","journal-title":"Neurosci. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cattepoel, S., Hanenberg, M., Kulic, L., and Nitsch, R.M. (2011). Chronic intranasal treatment with an anti-a\u03b2(30-42) scfv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018296"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1038\/mtna.2012.59","article-title":"In vivo SELEX for Identification of Brain-penetrating Aptamers","volume":"2","author":"Cheng","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2200057120","DOI":"10.1073\/pnas.2200057120","article-title":"Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets","volume":"120","author":"Correa","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","article-title":"Strategies to advance translational research into Brain Barriers","volume":"7","author":"Neuwelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sonvico, F., Clementino, A., Buttini, F., Colombo, G., Pescina, S., Guterres, S.S., Pohlmann, A.R., and Nicoli, S. (2018). Surface-Modified nanocarriers for nose-to-brain delivery: From bioadhesion to targeting. Pharmaceutics, 10.","DOI":"10.20944\/preprints201802.0077.v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.06.027","article-title":"Side by side comparison between dynamic versus static models of blood\u2013brain barrier in vitro: A permeability study","volume":"1109","author":"Santaguida","year":"2006","journal-title":"Brain Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0070-2153(07)80007-X","article-title":"Pathophysiology of the blood-brain barrier: Animal models and methods","volume":"80","author":"Hawkins","year":"2007","journal-title":"Curr. Top. Dev. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1359-6446(00)01632-9","article-title":"Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1)","volume":"6","author":"Kusuhara","year":"2001","journal-title":"Drug Discov. Today"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Masserini, M. (2012). Nanoparticles for brain drug delivery. ISRN Biochem., 2013.","DOI":"10.1155\/2013\/238428"},{"key":"ref_37","first-page":"11","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Pers. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/mp3001414","article-title":"Sodium caprate transiently opens claudin-5-containing barriers at tight junctions of epithelial and endothelial cells","volume":"9","author":"Vecchio","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-005-9038-4","article-title":"Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas","volume":"77","author":"Hall","year":"2006","journal-title":"J. Neuro-Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/bph.12218","article-title":"Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells","volume":"169","author":"Veszelka","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/jcbfm.2015.6","article-title":"Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumours","volume":"35","author":"Cooper","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1098-1128(200009)20:5<367::AID-MED3>3.0.CO;2-P","article-title":"Targeting drugs to the brain by redox chemical delivery systems","volume":"20","author":"Prokai","year":"2000","journal-title":"Med. Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1046\/j.1471-4159.1999.02002.x","article-title":"Transport of cationized anti-tetanus Fab\u20192 fragments across an In vitro blood-brain barrier model: Involvement of the transcytosis pathway","volume":"73","author":"Girod","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(98)00090-8","article-title":"Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems","volume":"36","author":"Bodor","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(00)03108-5","article-title":"Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin","volume":"889","author":"Zhang","year":"2001","journal-title":"Brain Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.022","article-title":"Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123","volume":"122","author":"Tosi","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nano.2012.08.004","article-title":"\u03b2-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain","volume":"9","author":"Venishetty","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.104.081000","article-title":"Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy","volume":"313","author":"Temsamani","year":"2005","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2009.09.012","article-title":"COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats","volume":"58","author":"Zibell","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2967\/jnumed.108.059162","article-title":"Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: Studies of healthy humans","volume":"50","author":"Muzi","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_52","first-page":"551","article-title":"Pluronic P85 enhances the delivery of digoxin to the brain: In Vitro and in Vivo studies","volume":"296","author":"Batrakova","year":"2001","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5173(03)00269-2","article-title":"RGD-anchored magnetic liposomes for monocytes\/neutrophils-mediated brain targeting","volume":"261","author":"Jain","year":"2003","journal-title":"Pharmaceutics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0006-8993(99)02089-2","article-title":"Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration","volume":"856","author":"Groothuis","year":"2000","journal-title":"Brain Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1345\/aph.19347","article-title":"Clinical pharmacology of encapsulated sustained-release cytarabine","volume":"34","author":"Murry","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_56","first-page":"2473","article-title":"Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain","volume":"26","author":"Fiore","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.carbpol.2012.02.051","article-title":"Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation","volume":"89","author":"Haque","year":"2012","journal-title":"Carbohydr. Polym."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: Physicochemical and therapeutic aspects","volume":"337","author":"Constantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157488507779422374","article-title":"Nasal Drug Delivery System-Factors Affecting and Applications","volume":"2","author":"Jadhav","year":"2007","journal-title":"Curr. Drug Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","article-title":"Nose-to-brain peptide delivery\u2014The potential of nanotechnology","volume":"26","author":"Samaridou","year":"2018","journal-title":"Biol. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"G\u00e4nger, S., and Schindowski, K. (2018). Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030116"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1248\/bpb.b14-00398","article-title":"The effect of cilia and the mucociliary clearance on successful drug delivery","volume":"38","author":"Gizurarson","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/1945892421990308","article-title":"Olfactory Perception and Different Decongestive Response of the Nasal Mucosa During Menstrual Cycle","volume":"35","author":"Bogdan","year":"2021","journal-title":"Am. J. Rhinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1753465811403348","article-title":"Nasal obstruction as a drug side effect","volume":"5","author":"Cingi","year":"2011","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood\u2013brain barrier: An excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.17219\/acem\/98960","article-title":"The radiological evaluation of the nasal cavity, conchae and nasal septum volumes by stereological method: A retrospective cone-beam computed tomography study","volume":"28","author":"Turhan","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_71","first-page":"Doc07","article-title":"Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses","volume":"9","author":"Beule","year":"2010","journal-title":"GMS Curr. Top. Otorhinolaryngol. Head Neck Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(99)00442-1","article-title":"Determination of baseline human nasal pH and the effect of intranasally administered buffers","volume":"198","author":"Washington","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.chom.2016.01.001","article-title":"The Interaction between Respiratory Pathogens and Mucus","volume":"19","author":"Zanin","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Dedrick, S., Akbari, M.J., Dyckman, S.K., Zhao, N., Liu, Y.Y., and Momeni, B. (2021). Impact of Temporal pH Fluctuations on the Coexistence of Nasal Bacteria in an in silico Community. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.613109"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Santacroce, L., Charitos, I.A., Ballini, A., Inchingolo, A.F., Luperto, P., De Nitto, E., and Topi, S. (2020). The Human Respiratory System and its Microbiome at a Glimpse. Biology, 9.","DOI":"10.3390\/biology9100318"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Kumpitsch, C., Koskinen, K., Sch\u00f6pf, V., and Moissl-Eichinger, C. (2019). The microbiome of the upper respiratory tract in health and disease. BMC Biol., 17.","DOI":"10.1186\/s12915-019-0703-z"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.4049\/jimmunol.181.6.4177","article-title":"Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid","volume":"181","author":"Do","year":"2008","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2500\/ajra.2010.24.3444","article-title":"Antimicrobial lipids: Novel innate defence molecules are elevated in sinus secretions of patients with chronic rhinosinusitis","volume":"24","author":"Lee","year":"2010","journal-title":"Am. J. Rhinol."},{"key":"ref_79","unstructured":"Dhamankar, V.S. (2013). Cytochrome P450-Mediated Drug Metabolizing Activity in the Nasal Mucosa. [Doctor of Philosophy Thesis, University of Iowa]."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0024-3205(91)90185-E","article-title":"Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa","volume":"48","author":"Tengamnuay","year":"1991","journal-title":"Life Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0973-8398.45032","article-title":"Bioavailability of intranasal drug delivery system","volume":"4","author":"Bhise","year":"2008","journal-title":"Asian J. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","article-title":"The role of brain barriers in fluid movement in the CNS: Is there a \u2018glymphatic\u2019 system?","volume":"135","author":"Abbott","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fnins.2019.00128","article-title":"Reimplantable Microdrive for Long-Term Chronic Extracellular Recordings in Freely Moving Rats","volume":"13","author":"Villavicencio","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biocel.2016.12.009","article-title":"A beginner\u2019s guide to tissue clearing","volume":"84","author":"Ariel","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_85","first-page":"101968","article-title":"An optimized protocol for iDISCO+ rat brain clearing, imaging, and analysis","volume":"4","author":"Branch","year":"2019","journal-title":"STAR Protoc."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Molbay, M., Kolabas, Z.I., Todorov, M.I., Ohn, T., and Ert\u00fcrk, A. (2021). A guidebook for DISCO tissue clearing. Mol. Syst. Biol., 17.","DOI":"10.15252\/msb.20209807"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"118635","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_88","first-page":"20","article-title":"Topical Applications and the Mucosa","volume":"40","author":"Surber","year":"2011","journal-title":"Cur. Prob. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","article-title":"Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs","volume":"36","author":"Lofts","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3329\/sjps.v4i1.8878","article-title":"Polymers and Permeation Enhancers: Specialized Components of Mucoadhesives","volume":"4","author":"Alexander","year":"2011","journal-title":"Stamford J. Pharm. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-817778-5.00009-9","article-title":"Nose-to-brain drug delivery","volume":"1","author":"Alexander","year":"2020","journal-title":"Nanopharmaceuticals"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2004.09.023","article-title":"Improved paracellular uptake by the combination of different types of permeation enhancers","volume":"288","author":"Guggi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.addr.2005.07.002","article-title":"Thiomers: A new generation of mucoadhesive polymers","volume":"57","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","article-title":"Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases","volume":"17","author":"Meredith","year":"2015","journal-title":"AAPS J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"33957","DOI":"10.1074\/jbc.M109.056309","article-title":"Translocation and endocytosis for cell-penetrating peptide internalization","volume":"284","author":"Jiao","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.febslet.2013.04.031","article-title":"Cell-penetrating peptides: 20 years later, where do we stand?","volume":"587","author":"Bechara","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.addr.2007.10.005","article-title":"Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans","volume":"60","author":"Ziegler","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_98","first-page":"387","article-title":"In vitro uptake and stability study of pVEC and its all-D analog","volume":"384","author":"Elmquist","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_99","first-page":"675","article-title":"Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. In Vitro","volume":"19","author":"Konsoula","year":"2005","journal-title":"Toxicol"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2005.09.047","article-title":"Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant","volume":"110","author":"Matsuyama","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.peptides.2009.03.018","article-title":"Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery","volume":"30","author":"Chen","year":"2009","journal-title":"Peptides"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.pharmthera.2008.11.001","article-title":"Airway mucus: The good, the bad, the sticky","volume":"121","author":"Evans","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpb.2015.11.004","article-title":"Mucus permeating thiolated self-emulsifying drug delivery systems","volume":"98","author":"Rohrer","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejpb.2008.09.028","article-title":"Mucoadhesive polymeric platforms for controlled drug delivery","volume":"71","author":"Andrews","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.apsb.2022.07.003","article-title":"Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders","volume":"13","author":"Awad","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drudis.2015.10.016","article-title":"Smart materials: In situ gel-forming systems for nasal delivery","volume":"21","author":"Karavasili","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425247.2018.1517741","article-title":"In situ gelling and mucoadhesive polymers: Why do they need each other?","volume":"15","author":"Wolf","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1248\/cpb.39.2155","article-title":"Study of Nasal Enzyme Activity towards Insulin. In Vitro","volume":"39","author":"Gizurarson","year":"1991","journal-title":"Chem. Pharm. Bull."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/1061186X.2013.789033","article-title":"Nanocarriers for oral drug delivery","volume":"21","author":"Zhang","year":"2013","journal-title":"J. Drug Target."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jps.10537","article-title":"Stability of PEGylated salmon calcitonin in nasal mucosa","volume":"93","author":"Na","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The Impact of PEGylation on Biological Therapies","volume":"22","author":"Veronese","year":"2018","journal-title":"BioDrugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijpharm.2014.06.029","article-title":"Thermoresponsive polymers: Insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications","volume":"472","author":"Kristl","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.apsb.2014.02.002","article-title":"Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route","volume":"4","author":"Pathak","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13346-019-00622-5","article-title":"Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles","volume":"9","author":"Nigam","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1208\/s12249-015-0294-0","article-title":"Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles","volume":"16","author":"Sharma","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1567201815666181004094707","article-title":"Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice","volume":"16","author":"Sunena","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11095-019-2662-z","article-title":"Increased Nose-to-Brain Delivery of Melatonin Mediated by Polycaprolactone Nanoparticles for the Treatment of Glioblastoma","volume":"36","author":"Nascimento","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin B"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2018.06.011","article-title":"Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery","volume":"129","author":"Salade","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jps.21939","article-title":"Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations","volume":"99","author":"Migliore","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijpharm.2017.07.030","article-title":"Brain targeting efficiency of antimigraine drug loaded mucoadhesive intranasal nanoemulsion","volume":"529","author":"Abdou","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1208\/s12249-016-0552-9","article-title":"Quetiapine Nanoemulsion for Intranasal Drug Delivery: Evaluation of Brain-Targeting Efficiency","volume":"18","author":"Boche","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"111076","DOI":"10.1016\/j.colsurfb.2020.111076","article-title":"Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation","volume":"193","author":"Hady","year":"2020","journal-title":"Colloids Surf. B"},{"key":"ref_125","first-page":"17590","article-title":"Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","article-title":"Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson\u2019s Disease","volume":"12","author":"Gartziandia","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biopha.2017.07.067","article-title":"Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study","volume":"94","author":"Pokharkar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.3109\/10717544.2014.971196","article-title":"Non-ionic surfactants as novel intranasal absorption enhancers: In vitro and in vivo characterization","volume":"23","author":"Li","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Espinoza, L.C., Silva-Abreu, M., Clares, B., Rodr\u00edguez-Lagunas, M.J., Halbaut, L., Ca\u00f1as, M.-A., and Calpena, A.C. (2019). Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11020064"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejpb.2017.07.011","article-title":"Rhamnolipids as epithelial permeability enhancers for macromolecular therapeutics","volume":"119","author":"Perinelli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.apsb.2016.04.001","article-title":"Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides","volume":"6","author":"Lin","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2014.11.004","article-title":"Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides","volume":"197","author":"Kamei","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jconrel.2020.01.016","article-title":"Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity","volume":"319","author":"Khafagy","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"17641","DOI":"10.1038\/s41598-018-36210-9","article-title":"Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction","volume":"8","author":"Kamei","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2019.09.008","article-title":"Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery","volume":"144","author":"Dalpiaz","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_137","first-page":"393","article-title":"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.22382","article-title":"Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres","volume":"100","author":"Gavini","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejpb.2012.10.010","article-title":"Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting","volume":"83","author":"Gavini","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2018.10.071","article-title":"Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride","volume":"553","author":"Li","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2017.07.077","article-title":"Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide","volume":"530","author":"Kanazawa","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ajps.2015.11.121","article-title":"Brain targeted delivery of paclitaxel using endogenous ligand","volume":"11","author":"Acharya","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.10.011","article-title":"Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression","volume":"48","author":"Haque","year":"2014","journal-title":"J. Psych. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.msec.2016.04.089","article-title":"Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics","volume":"66","author":"Sawant","year":"2016","journal-title":"Mater. Sci. Eng. C-Mater."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijbiomac.2017.11.031","article-title":"Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment","volume":"108","author":"Singh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.colsurfb.2017.08.031","article-title":"Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies","volume":"159","author":"Salatin","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.03.055","article-title":"Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro","volume":"543","author":"Colombo","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.nano.2019.01.014","article-title":"Effective encapsulation of apomorphine into biodegradable polymeric nanoparticles through a reversible chemical bond for delivery across the blood\u2013brain barrier","volume":"17","author":"Tan","year":"2019","journal-title":"Nanomed. NBM"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijbiomac.2013.06.041","article-title":"Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery","volume":"61","author":"Kumar","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.sjbs.2019.11.008","article-title":"Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia","volume":"27","author":"Ahmad","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13346-014-0208-9","article-title":"Gelatin nanoparticles enhance the neuroprotective effects of intranasally administered osteopontin in rat ischemic stroke model","volume":"4","author":"Joachim","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1002\/jgm.506","article-title":"Recombinant AAV-mediated gene delivery to the central nervous system","volume":"6","author":"Tenenbaum","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.nano.2013.10.009","article-title":"Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats","volume":"10","author":"Zhao","year":"2014","journal-title":"Nanomed. NBM"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1021\/mp5008376","article-title":"Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation","volume":"12","author":"Yadav","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijbiomac.2019.02.005","article-title":"Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery","volume":"129","author":"Piazzini","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.carbpol.2013.08.027","article-title":"Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats","volume":"99","author":"Bshara","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2014.06.037","article-title":"Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer","volume":"122","author":"Devkar","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jsps.2016.07.003","article-title":"Direct and enhanced delivery of nanoliposomes of anti-schizophrenic agent to the brain through nasal route","volume":"25","author":"Upadhyay","year":"2017","journal-title":"Saudi Pharm J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.colsurfb.2016.08.011","article-title":"Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery","volume":"147","author":"Hao","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.nano.2015.12.374","article-title":"Intranasal brain delivery of cationic nanoemulsion-encapsulated TNF\u03b1 siRNA in prevention of experimental neuroinflammation","volume":"12","author":"Yadav","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.colsurfb.2019.05.016","article-title":"Poloxamer-407 thickened lipid colloidal system of agomelatine for brain targeting: Characterization, brain pharmacokinetic study and behavioral study on Wistar rats","volume":"181","author":"Ahmed","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2018.11.025","article-title":"Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study","volume":"174","author":"Praveen","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpharm.2019.04.076","article-title":"Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice","volume":"565","author":"Iqbal","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_168","first-page":"29","article-title":"Nose-to-brain delivery of levetiracetam after intranasal administration to mice","volume":"564","author":"Bicker","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jddst.2015.08.003","article-title":"Formulation and evaluation of thermoreversible mucoadhesive in-situ gel for intranasal delivery of naratriptan hydrochloride","volume":"29","author":"Shelke","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejps.2016.05.008","article-title":"Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration","volume":"91","author":"Shah","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17425247.2018.1471058","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region","volume":"15","author":"Agrawal","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.2174\/0929867321666140217125857","article-title":"Peptide therapeutics in neurodegenerative disorders","volume":"21","author":"Tiwari","year":"2014","journal-title":"Curr. Med Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.biopha.2018.04.025","article-title":"Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases","volume":"103","author":"Baig","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coph.2019.02.007","article-title":"Peptides in clinical development for the treatment of brain tumors","volume":"47","author":"Guidotti","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10717549709051892","article-title":"Olfactory absorption of insulin to the brain","volume":"4","author":"Sigurdsson","year":"1997","journal-title":"Drug Deliv."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acs.molpharmaceut.6b01134","article-title":"Effect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouse","volume":"14","author":"Kamei","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2008.09.076","article-title":"Effect of cell-penetrating peptides on the nasal absorption of insulin","volume":"133","author":"Khafagy","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","article-title":"Nose-to-brain delivery of insulin enhanced by a nanogel carrier","volume":"270","author":"Picone","year":"2018","journal-title":"J Control Release"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1248\/cpb.40.1569","article-title":"Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits","volume":"40","author":"Maitani","year":"1992","journal-title":"Chem. Pharm. Bull."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.2042-7158.1985.tb05024.x","article-title":"Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel","volume":"37","author":"Morimoto","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0378-5173(96)04441-9","article-title":"Intranasal mucociliary of putative bioadhesive polymer gels","volume":"135","author":"Zhou","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2005.10.049","article-title":"Influence of deposition and spray pattern of nasal powders on insulin bioavailability","volume":"310","author":"Pringels","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0168-3659(84)90017-8","article-title":"Powder dosage form of insulin for nasal administration","volume":"1","author":"Tsuneji","year":"1984","journal-title":"J. Control. Release"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0378-5173(96)04569-3","article-title":"Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems","volume":"139","author":"Oechslein","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.103.063222","article-title":"Brain uptake of the glucagon-like peptide1 antagonist exendin (9\u201339) after intranasal administration","volume":"309","author":"Banks","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-i to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.expneurol.2009.03.021","article-title":"Intranasal administration of IGF-1 attenuates hypoxic\u2013ischemic brain injury in neonatal rats","volume":"217","author":"Lin","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2016.01.017","article-title":"Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model","volume":"224","author":"Zhao","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","article-title":"The state of-play and future of antibody therapeutics","volume":"122","author":"Elgundi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_194","unstructured":"(2023, June 09). FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease, Available online: https:\/\/www.fda.gov\/drugs\/our-perspective\/fdas-decision-approve-new-treatment-alzheimers-disease."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2009.08.005","article-title":"Intranasal delivery of ESBA105, a TNF-alphainhibitory scFv antibody fragment to the brain","volume":"215","author":"Furrer","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","article-title":"Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting","volume":"25","author":"Chu","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Musumeci, T., Di Benedetto, G., Carbone, C., Bonaccorso, A., Amato, G., Faro, M.J.L., Burgaletto, C., Puglisi, G., Bernardini, R., and Cantarella, G. (2022). Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer\u2019s Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10050985"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cbi.2019.05.028","article-title":"Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases","volume":"308","author":"Mehta","year":"2019","journal-title":"Chem.-Biol. Interact."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jconrel.2021.12.034","article-title":"Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy","volume":"342","author":"Yang","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/mt.2011.291","article-title":"Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain","volume":"20","author":"Kim","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13311-019-00736-1","article-title":"Nucleic acid therapeutics for neurological diseases","volume":"16","author":"Watts","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/ard.1991.1.11","article-title":"Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos","volume":"1","author":"Dagle","year":"1991","journal-title":"Antisense Res. Dev."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/j.pain.0000000000002154","article-title":"Intranasal delivery of an antisense oligonucleotide to the RNA-binding protein HuR relieves nerve injury-induced neuropathic pain","volume":"162","author":"Borgonetti","year":"2021","journal-title":"Pain"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s13311-020-00958-8","article-title":"Targeting the RNA-Binding Protein HuR Alleviates Neuroinflammation in Experimental Autoimmune Encephalomyelitis: Potential Therapy for Multiple Sclerosis","volume":"18","author":"Borgonetti","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/10717544.2020.1760960","article-title":"RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery","volume":"27","author":"Hao","year":"2020","journal-title":"Drug Deliv."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Samaridou, E., Walgrave, H., Salta, E., \u00c1lvarez, D.M., Castro-L\u00f3pez, V., Loza, M., and Alonso, M.J. (2020). Nose-to-brain delivery of enveloped RNA-cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases. Biomaterials, 230.","DOI":"10.1016\/j.biomaterials.2019.119657"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jbm.1227","article-title":"In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA","volume":"59","author":"Park","year":"2002","journal-title":"J. Biomat. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/10611860903450031","article-title":"Nasal delivery of antisense oligonucleotides: In vitro evaluation of a thiomer\/glutathione microparticulate delivery system","volume":"18","author":"Vetter","year":"2010","journal-title":"J. Drug Target."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jps.21887","article-title":"Thiolated polycarbophil as an adjuvant for permeation enhancement in nasal delivery of antisense oligonucleotides","volume":"99","author":"Vetter","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0028-3908(67)90005-6","article-title":"Some effects of progesterone and related steroids on the central nervous system","volume":"6","author":"Gyermek","year":"1967","journal-title":"Int. J. Neuropharm."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0960-0760(90)90490-C","article-title":"Neurosteroids: A new brain function?","volume":"37","author":"Baulieu","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2174\/138161208786848838","article-title":"Neuroactive steroids as endogenous modulators of anxiety","volume":"14","author":"Eser","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pharmthera.2007.06.001","article-title":"Progesterone: Therapeutic opportunities for neuroprotection and myelin repair","volume":"116","author":"Schumacher","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2010.05.033","article-title":"Brain distribution and behavioural effects of progesterone and pregnenolone after intranasal or intravenous administration","volume":"641","author":"Ducharme","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuroscience.2008.09.003","article-title":"Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats","volume":"157","author":"Topic","year":"2008","journal-title":"Neuroscience"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2004.02.010","article-title":"Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats","volume":"58","author":"Verhoef","year":"2004","journal-title":"Eur. Pharm. Biopharm."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1023\/A:1015816716544","article-title":"Nasal absorption enhancement of 17-b-oestradiol by dimethyl-b-cyclodextrin in rabbits and rats","volume":"7","author":"Hermens","year":"1990","journal-title":"Pharm. Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2006.02.055","article-title":"Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method","volume":"317","author":"Wang","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/10611860802382777","article-title":"Delivery of testosterone to the brain by intranasal administration: Comparison to intravenous testosterone","volume":"17","author":"Banks","year":"2009","journal-title":"J. Drug Target."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euroneuro.2008.08.003","article-title":"Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone","volume":"19","author":"Mattern","year":"2009","journal-title":"Eur. Neuropsychopharm."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.yhbeh.2011.01.007","article-title":"Intranasal administration of testosterone increased immobile-sniffing, exploratory behavior, motor behavior and grooming behavior in rats","volume":"59","author":"Zhang","year":"2011","journal-title":"Horm. Behav."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s13311-020-00985-5","article-title":"Intranasal Allopregnanolone Confers Rapid Seizure Protection: Evidence for Direct Nose-to-Brain Delivery","volume":"18","author":"Zolkowska","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-3223(95)00180-8","article-title":"Brain potential changes after intranasal vs. intravenous administration of vasopressin: Evidence for a direct nose\u2013brain pathway for peptide effects in humans","volume":"39","author":"Pietrowsky","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.113.02860","article-title":"Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked","volume":"63","author":"Derad","year":"2014","journal-title":"Hypertension"},{"key":"ref_226","first-page":"28599","article-title":"Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model. Molecular Therapeutics","volume":"26","author":"Buchthal","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"102107","DOI":"10.1016\/j.nano.2019.102107","article-title":"Nose-to-brain codelivery of repurposed simvastatin and BDNF synergistically attenuates LPS-induced neuroinflammation","volume":"23","author":"Manickavasagam","year":"2020","journal-title":"Nanomed. NBM"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2741\/e209","article-title":"Intranasal delivery of calcitonin gene-related peptide reduces cerebral vasospasm in rats","volume":"2","author":"Sun","year":"2010","journal-title":"Front. Biosci."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0928-0987(01)00094-X","article-title":"Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin","volume":"13","author":"Morimoto","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2009.10.031","article-title":"Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid\u2122 Fatty Acid based delivery system, and by N-trimethyl chitosan chloride","volume":"385","author":"Lubbe","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0306-4530(96)00012-1","article-title":"A nose\u2013brain pathway for psychotropic peptides: Evidence from a brain evoked potential study with cholecystokinin","volume":"21","author":"Pietrowsky","year":"1996","journal-title":"Psychoneuroendocrinology"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"533.1","DOI":"10.1096\/fasebj.27.1_supplement.533.1","article-title":"Intranasal Delivery of a Cystatin C-peptide as Therapy for Alzheimer\u2019s Disease","volume":"27","author":"Shaw","year":"2013","journal-title":"FASEB J."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1007\/s12035-016-0034-9","article-title":"Intranasal Delivery of a Caspase-1 Inhibitor in the Treatment of Global Cerebral Ischemia","volume":"54","author":"Zhao","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2005.07.008","article-title":"Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia","volume":"387","author":"Yu","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_235","first-page":"231","article-title":"An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer\u2019s Disease","volume":"55","author":"Strehaiano","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1248\/bpb.b12-00029","article-title":"Low molecular weight (1\u2009kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db\/db mice","volume":"35","author":"Kim","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10517-010-1058-1","article-title":"Antiamnestic effects of antibodies to glutamate in experimental Alzheimer\u2019s disease","volume":"150","author":"Gorbatov","year":"2010","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/jpet.107.132381","article-title":"Delivery of galanin-like peptide to the brain: Targeting with intranasal delivery and cyclodextrins","volume":"325","author":"Nonaka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer\u2019s Disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Capsoni, S., Marinelli, S., Ceci, M., Vignone, D., Amato, G., Malerba, F., Paoletti, F., Meli, G., Viegi, A., and Pavone, F. (2012). Correction: Intranasal \u201cpainless\u201d Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice. PLoS ONE, 7.","DOI":"10.1371\/annotation\/97b6c799-1ebc-4e7b-8f86-47c1130dc00e"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejpb.2011.10.012","article-title":"A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid-\u03b225\u201335-treated rats following intranasal administration","volume":"80","author":"Wu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-3659(99)00271-0","article-title":"Evaluation of starch\u2013maltodextrin\u2013carbopol\u00ae 974 P mixtures for the nasal delivery of insulin in Rabbits","volume":"66","author":"Callens","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-5173(01)00708-6","article-title":"Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides","volume":"222","author":"Illum","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","article-title":"Intranasal administration of insulin-like growth factor-I bypasses the blood\u2013brain barrier and protects against focal cerebral ischemic damage","volume":"187","author":"Liu","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-beta to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2004.02.011","article-title":"Intranasal administration of interferon beta bypasses the blood\u2013brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis","volume":"151","author":"Ross","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1210\/en.2005-1016","article-title":"Brain uptake of intranasally applied radioiodinated leptin in Wistar rats","volume":"147","author":"Fliedner","year":"2006","journal-title":"Endocrinology"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","article-title":"Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Zhao, Y.Z., Jin, R.R., Yang, W., Xiang, Q., Yu, W.Z., Lin, Q., Tian, F.R., Mao, K.L., Lv, C.Z., and Wang, Y.X.J. (2016). Using gelatin nanoparticle mediated intranasal delivery of neuropeptide substance P to enhance neuro-recovery in hemiparkinsonian rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148848"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bdd.621","article-title":"Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: A microdialysis study","volume":"29","author":"Cheng","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.peptides.2011.05.002","article-title":"Antinociceptive properties of nasal delivery of Neurotoxin-loaded nanoparticles coated with polysorbate-80","volume":"32","author":"Ruan","year":"2012","journal-title":"Peptides"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.nano.2018.10.013","article-title":"Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke","volume":"18","author":"Li","year":"2019","journal-title":"Nanomed. NBM"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.33549\/physiolres.933513","article-title":"Sedative effects of intranasal oxytocin in rabbits and rhesus monkeys","volume":"65","author":"Hess","year":"2016","journal-title":"Physiol. Res."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Monte, O.D., Noble, P.L., Turchi, J., Cummins, A., and Averbeck, B.B. (2014). CSF and blood oxytocin concentration changes following intranasal delivery in macaque. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103677"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"14239","DOI":"10.1523\/JNEUROSCI.3878-07.2007","article-title":"Systemic and nasal delivery of orexin- A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates","volume":"27","author":"Deadwyler","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/jpet.108.145565","article-title":"Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system","volume":"328","author":"Dhuria","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-5728(92)90215-7","article-title":"Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites","volume":"40","author":"Gordon","year":"1992","journal-title":"J. Neuroimmunol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice","volume":"25","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2203182","DOI":"10.1002\/smll.202203182","article-title":"Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer\u2019s Disease Therapy","volume":"18","author":"Yang","year":"2022","journal-title":"Small"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.nano.2016.01.002","article-title":"Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain","volume":"12","author":"Kim","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainres.2009.09.039","article-title":"Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo","volume":"1303","author":"Veronesi","year":"2009","journal-title":"Brain Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cej.2018.03.176","article-title":"Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues","volume":"346","author":"Kaur","year":"2018","journal-title":"Chem. Eng. J."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","article-title":"Odorranalectinconjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration","volume":"151","author":"Wen","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neulet.2009.06.060","article-title":"The dose effectiveness of intranasal VEGF in treatment of experimental stroke","volume":"461","author":"Yang","year":"2009","journal-title":"Neurosci. Lett."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2008.10.090","article-title":"Direct transport of VEGF from the nasal cavity to brain","volume":"449","author":"Yang","year":"2009","journal-title":"Neurosci. Lett."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003495-199039030-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile","volume":"39","author":"Brogden","year":"1990","journal-title":"Drugs"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425247.2016.1206074","article-title":"Emerging delivery platforms for mucosal administration of biopharmaceuticals: A critical update on nasal, pulmonary and oral routes","volume":"14","author":"Thwala","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"T1D Exchange Intranasal Glucagon Investigators, A Promising Alternative to Intramuscular Glucagon in Youth with Type 1 Diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00003495-199039040-00005","article-title":"Nafarelin: A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions","volume":"39","author":"Chrisp","year":"1990","journal-title":"Drugs"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"24976","DOI":"10.52965\/001c.24976","article-title":"Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures","volume":"13","author":"Kaneb","year":"2021","journal-title":"Orthop. Rev."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","article-title":"Advanced formulations for intranasal delivery of biologics","volume":"553","author":"Rohrer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_274","unstructured":"U.S. Food and Drugs Administration (2023, October 20). Center for Drug Evaluation and Research Drug Approvals and Databases, Available online: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databasesInformation."},{"key":"ref_275","unstructured":"National Library of Medicine (2023, November 03). Available online: https:\/\/www.clinicaltrials.gov."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/66\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:45:25Z","timestamp":1760132725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":275,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["pharmaceutics16010066"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16010066","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,31]]}}}